JP6159254B2 - 乳がん転移の診断、予後診断、および処置のための方法 - Google Patents

乳がん転移の診断、予後診断、および処置のための方法 Download PDF

Info

Publication number
JP6159254B2
JP6159254B2 JP2013532235A JP2013532235A JP6159254B2 JP 6159254 B2 JP6159254 B2 JP 6159254B2 JP 2013532235 A JP2013532235 A JP 2013532235A JP 2013532235 A JP2013532235 A JP 2013532235A JP 6159254 B2 JP6159254 B2 JP 6159254B2
Authority
JP
Japan
Prior art keywords
maf
gene
metastasis
breast cancer
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013532235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541339A (ja
JP2013541339A5 (enExample
Inventor
カブレ， ロジェル ゴミス
カブレ， ロジェル ゴミス
スニエル， マリア タラゴナ
スニエル， マリア タラゴナ
エスタペ， アナ アルナル
エスタペ， アナ アルナル
ミリカ パブロビック，
ミリカ パブロビック，
Original Assignee
フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ）
フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ）
インスティトゥーシオ カタラーナ デ レセルカ イ エストゥディス アバンサッツ
インスティトゥーシオ カタラーナ デ レセルカ イ エストゥディス アバンサッツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201031478A external-priority patent/ES2379918B1/es
Application filed by フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ）, フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ）, インスティトゥーシオ カタラーナ デ レセルカ イ エストゥディス アバンサッツ, インスティトゥーシオ カタラーナ デ レセルカ イ エストゥディス アバンサッツ filed Critical フンダシオ インスティトゥト デ レセルカ ビオメディカ（イエレベ バルセロナ）
Publication of JP2013541339A publication Critical patent/JP2013541339A/ja
Publication of JP2013541339A5 publication Critical patent/JP2013541339A5/ja
Application granted granted Critical
Publication of JP6159254B2 publication Critical patent/JP6159254B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
JP2013532235A 2010-10-06 2011-10-05 乳がん転移の診断、予後診断、および処置のための方法 Active JP6159254B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ESP201031478 2010-10-06
ES201031478A ES2379918B1 (es) 2010-10-06 2010-10-06 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
ESP201131073 2011-06-27
ES201131073 2011-06-27
PCT/ES2011/070693 WO2012045905A2 (es) 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017011967A Division JP6571698B2 (ja) 2010-10-06 2017-01-26 乳がん転移の診断、予後診断、および処置のための方法

Publications (3)

Publication Number Publication Date
JP2013541339A JP2013541339A (ja) 2013-11-14
JP2013541339A5 JP2013541339A5 (enExample) 2014-11-27
JP6159254B2 true JP6159254B2 (ja) 2017-07-12

Family

ID=45099129

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013532235A Active JP6159254B2 (ja) 2010-10-06 2011-10-05 乳がん転移の診断、予後診断、および処置のための方法
JP2017011967A Active JP6571698B2 (ja) 2010-10-06 2017-01-26 乳がん転移の診断、予後診断、および処置のための方法
JP2018054132A Pending JP2018099132A (ja) 2010-10-06 2018-03-22 乳がん転移の診断、予後診断、および処置のための方法
JP2019146185A Active JP6946385B2 (ja) 2010-10-06 2019-08-08 乳がん転移の診断、予後診断、および処置のための方法
JP2021150170A Pending JP2021192636A (ja) 2010-10-06 2021-09-15 乳がん転移の診断、予後診断、および処置のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017011967A Active JP6571698B2 (ja) 2010-10-06 2017-01-26 乳がん転移の診断、予後診断、および処置のための方法
JP2018054132A Pending JP2018099132A (ja) 2010-10-06 2018-03-22 乳がん転移の診断、予後診断、および処置のための方法
JP2019146185A Active JP6946385B2 (ja) 2010-10-06 2019-08-08 乳がん転移の診断、予後診断、および処置のための方法
JP2021150170A Pending JP2021192636A (ja) 2010-10-06 2021-09-15 乳がん転移の診断、予後診断、および処置のための方法

Country Status (13)

Country Link
US (3) US10047398B2 (enExample)
EP (3) EP3091085B1 (enExample)
JP (5) JP6159254B2 (enExample)
KR (2) KR101944555B1 (enExample)
CN (2) CN103339265B (enExample)
AR (1) AR083357A1 (enExample)
AU (4) AU2011311452B2 (enExample)
BR (1) BR112013008505B1 (enExample)
CA (1) CA2813674C (enExample)
DK (2) DK2626431T3 (enExample)
ES (3) ES2721639T3 (enExample)
MX (2) MX344315B (enExample)
WO (1) WO2012045905A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3091085B1 (en) * 2010-10-06 2019-02-27 Institució Catalana de Recerca I Estudis Avançats Method of designing a therapy for breast cancer metastasis
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
WO2014140896A2 (es) * 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
CA2906394A1 (en) * 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) * 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3458610T3 (da) * 2016-05-25 2021-06-07 Inbiomotion Sl Terapeutisk behandling af brystcancer baseret på c-MAF-status
KR101896558B1 (ko) 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN107699619B (zh) * 2017-11-17 2019-02-22 柳超 lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
JP2023079997A (ja) 2021-11-29 2023-06-08 東洋インキＳｃホールディングス株式会社 活性エネルギー線硬化型インクジェットインキ及び印刷物
CN114574577A (zh) * 2022-01-04 2022-06-03 中山大学孙逸仙纪念医院 Mettl16基因及其用途
CN119614707A (zh) * 2025-01-13 2025-03-14 中山大学 ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE4013632A1 (de) 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
HK1039108A1 (zh) 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以n-氰甲基酰胺作为蛋白酶抑制剂
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
JP2005509961A (ja) 2001-11-13 2005-04-14 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 較正を導き出す方法および画像処理の方法
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005029067A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1730308A4 (en) 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP1941050B1 (en) 2005-09-20 2017-04-26 Janssen Diagnostics, LLC Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
EP1931994A2 (en) 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2008145125A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
CA2702805A1 (en) 2007-10-18 2009-04-23 University Health Network Clioquinol for the treatment of hematological malignancies
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
CN102123708A (zh) 2008-06-06 2011-07-13 大学健康网络 用于治疗恶性血液疾病的8-羟基喹啉衍生物
EP2297360A1 (en) 2008-07-02 2011-03-23 Assistance Publique - Hôpitaux de Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011017687A1 (en) 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
EP3091085B1 (en) 2010-10-06 2019-02-27 Institució Catalana de Recerca I Estudis Avançats Method of designing a therapy for breast cancer metastasis
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
WO2013075059A1 (en) 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3458610T3 (da) 2016-05-25 2021-06-07 Inbiomotion Sl Terapeutisk behandling af brystcancer baseret på c-MAF-status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Also Published As

Publication number Publication date
KR20190009835A (ko) 2019-01-29
EP3517630A1 (en) 2019-07-31
AU2016266009A1 (en) 2016-12-15
KR101944555B1 (ko) 2019-02-01
MX344315B (es) 2016-12-13
HK1187377A1 (en) 2014-04-04
EP2626431B1 (en) 2015-09-16
KR20140071946A (ko) 2014-06-12
US20190169693A1 (en) 2019-06-06
JP2013541339A (ja) 2013-11-14
BR112013008505B1 (pt) 2023-01-24
US20140057796A1 (en) 2014-02-27
CN103339265A (zh) 2013-10-02
WO2012045905A2 (es) 2012-04-12
ES2911505T3 (es) 2022-05-19
KR102240323B1 (ko) 2021-04-14
JP2018099132A (ja) 2018-06-28
AU2021203599B2 (en) 2024-10-10
US10047398B2 (en) 2018-08-14
CN103339265B (zh) 2018-03-30
CA2813674A1 (en) 2012-04-12
MX2013003880A (es) 2013-12-02
US20220049316A1 (en) 2022-02-17
JP6946385B2 (ja) 2021-10-06
US11072831B2 (en) 2021-07-27
AU2019201493A1 (en) 2019-03-28
JP2021192636A (ja) 2021-12-23
EP3517630B1 (en) 2022-01-19
ES2721639T3 (es) 2019-08-02
AU2019201493B2 (en) 2021-03-11
EP3091085A1 (en) 2016-11-09
JP2019195340A (ja) 2019-11-14
CA2813674C (en) 2020-11-24
AU2011311452A1 (en) 2013-05-09
MX382266B (es) 2025-03-13
AU2011311452B2 (en) 2016-09-01
DK3091085T3 (da) 2019-05-06
BR112013008505A2 (pt) 2016-07-05
AU2021203599A1 (en) 2021-07-01
CN108192972A (zh) 2018-06-22
WO2012045905A3 (es) 2012-06-21
US12312642B2 (en) 2025-05-27
CN108192972B (zh) 2022-09-09
ES2562274T3 (es) 2016-03-03
EP2626431A2 (en) 2013-08-14
AU2016266009B2 (en) 2018-12-06
JP6571698B2 (ja) 2019-09-04
DK2626431T3 (en) 2015-12-21
JP2017104115A (ja) 2017-06-15
AR083357A1 (es) 2013-02-21
EP3091085B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
JP6571698B2 (ja) 乳がん転移の診断、予後診断、および処置のための方法
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
JP2016518815A (ja) 転移性がんの診断、予後、および処置の方法
HK40011542A (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK40011542B (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK1229858B (en) Method of designing a therapy for breast cancer metastasis
HK1229858A (en) Method of designing a therapy for breast cancer metastasis
HK1229858A1 (en) Method of designing a therapy for breast cancer metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170609

R150 Certificate of patent or registration of utility model

Ref document number: 6159254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250